NCT04302025 2026-04-03
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
Genentech, Inc.
Centre Leon Berard
Rigshospitalet, Denmark
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Helsinki University Central Hospital
Oslo University Hospital
The Netherlands Cancer Institute
Oslo University Hospital